ArticleJournal of cancer research and clinical oncology2019
Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018.
Article in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Inter-Observer Reproducibility of [18F]FDG PET/CT Radiomic Features in Primary Breast Carcinoma.Journal of imaging · 2026Article
- Guestimating Molecular Subtyping of Breast Cancer by Ki67 in the Era of Artificial Intelligence.International journal of breast cancer · 2026Article
- The role of magnetic resonance imaging (MRI) in breast cancer molecular subtypes.Polish journal of radiology · 2026Review
- Identification and prognostic significance of Ki-67-related genes in triple negative breast cancer.Discover oncology · 2025Article
- Molecular pathology in breast disease: diagnostic, prognostic, and therapeutic tools.Virchows Archiv : an international journal of pathology · 2024Review
- Whole-Tumor ADC Texture Analysis Is Able to Predict Breast Cancer Receptor Status.Diagnostics (Basel, Switzerland) · 2023Article
- Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.Virchows Archiv : an international journal of pathology · 2022Article
- Knockdown of circ_0067934 inhibits gastric cancer cell proliferation, migration and invasion via the miR‑1301‑3p/KIF23 axis.Molecular medicine reports · 2022Article
- Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy.Scientific reports · 2022Article
- Glioblastoma stem cell (GSC)-derived PD-L1-containing exosomes activates AMPK/ULK1 pathway mediated autophagy to increase temozolomide-resistance in glioblastoma.Cell & bioscience · 2021Article
- Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.Breast cancer research and treatment · 2020Article
- Accuracy and efficiency of an artificial intelligence tool when counting breast mitoses.Diagnostic pathology · 2020Article
- Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer.Breast (Edinburgh, Scotland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAccurate monitoring of predictive markers is of utmost importance as oncological treatment decisions almost entirely depend on these factors. In this study, we conducted a quality control assessment on hormone receptors, Her2 status, Ki67 Labelling Index (LI) and histological grading in breast cancer over 4 years (2015-2018).
methodsAltogether 2214 consecutive breast cancer cases were included. Data on estrogen (ER) and progesterone receptors (PR), Her2 and Ki67, were available in all cases and were tested mostly on preoperative biopsies, in selected cases on postoperative surgical specimens. ER, PR, and Ki67 were assessed with immunohistochemistry (IHC), Her2 status with IHC and fluorescence in situ hybridization.
resultsER/PR were positive in 74-79% cases, ER/PR/Her2 negative in 6.16-10.70% and Her2 positive in 11.49-13.88%/year. Ki67 had median values as 15-17.5% in ER/PR-positive cases, 55-60% in triple-negative cases and 30-32.50% in Her2-positive cases. Histological grading distribution for well (G1), moderately (G2) and poorly (G3) differentiated carcinomas was 15.8-19.1% for G1, 54.2-54.8% for G2 and 21.7-23.7% for G3 cases. Variation in yearly distributions was not significant in any of these markers.
conclusionsPredictive markers displayed a yearly similar distribution in breast cancer cases independently of grading or of intrinsic subtypes. These results point to a qualitative high performance of predictive marker assessment in breast cancer, corresponding to expected on average positivity rate per marker and per year. It is recommended to monitor positivity rate of ER, PR, Ki67 and Her2 yearly or periodically to comply with quality assurance requirements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.